687 related articles for article (PubMed ID: 10368524)
1. Effects of oral contraceptives on hemostasis and thrombosis.
Rosing J; Tans G
Am J Obstet Gynecol; 1999 Jun; 180(6 Pt 2):S375-82. PubMed ID: 10368524
[TBL] [Abstract][Full Text] [Related]
2. Normalized activated protein C ratio itself not associated with increased risk of venous thromboembolism.
Heinemann LA; Assmann A; Spannagl M; Schramm W; Dick A; Kluft C; de Maat MP
Contraception; 1998 Nov; 58(5):321-2. PubMed ID: 9883389
[TBL] [Abstract][Full Text] [Related]
3. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study.
Rosing J; Middeldorp S; Curvers J; Christella M; Thomassen LG; Nicolaes GA; Meijers JC; Bouma BN; Büller HR; Prins MH; Tans G
Lancet; 1999 Dec; 354(9195):2036-40. PubMed ID: 10636369
[TBL] [Abstract][Full Text] [Related]
4. Resistance to activated protein C in healthy women taking oral contraceptives.
Olivieri O; Friso S; Manzato F; Guella A; Bernardi F; Lunghi B; Girelli D; Azzini M; Brocco G; Russo C
Br J Haematol; 1995 Oct; 91(2):465-70. PubMed ID: 8547095
[TBL] [Abstract][Full Text] [Related]
5. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen.
Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Büller HR; Vandenbroucke JP
Lancet; 1995 Dec; 346(8990):1593-6. PubMed ID: 7500751
[TBL] [Abstract][Full Text] [Related]
6. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
Farmer RD; Lawrenson RA; Thompson CR; Kennedy JG; Hambleton IR
Lancet; 1997 Jan; 349(9045):83-8. PubMed ID: 8996419
[TBL] [Abstract][Full Text] [Related]
7. Effects on hemostatic variables of desogestrel- and gestodene-containing oral contraceptives in comparison with levonorgestrel-containing oral contraceptives: a review.
Winkler UH
Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 2):S51-61. PubMed ID: 9753311
[TBL] [Abstract][Full Text] [Related]
8. Resistance to activated protein C in women using oral contraceptives.
Spannagl M; Dick A; Assmann A; Heinemann L; Schramm W
Semin Thromb Hemost; 1998; 24(5):423-30. PubMed ID: 9834008
[TBL] [Abstract][Full Text] [Related]
9. Resistance to activated protein C, highly prevalent amongst users of oral contraceptives with venous thromboembolism.
Bennet L; Odeberg H
J Intern Med; 1998 Jul; 244(1):27-32. PubMed ID: 9698021
[TBL] [Abstract][Full Text] [Related]
10. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives.
Rosing J; Tans G; Nicolaes GA; Thomassen MC; van Oerle R; van der Ploeg PM; Heijnen P; Hamulyak K; Hemker HC
Br J Haematol; 1997 Apr; 97(1):233-8. PubMed ID: 9136971
[TBL] [Abstract][Full Text] [Related]
11. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective.
Price DT; Ridker PM
Ann Intern Med; 1997 Nov; 127(10):895-903. PubMed ID: 9382368
[TBL] [Abstract][Full Text] [Related]
12. Smoking and use of oral contraceptives: impact on thrombotic diseases.
Lidegaard O
Am J Obstet Gynecol; 1999 Jun; 180(6 Pt 2):S357-63. PubMed ID: 10368521
[TBL] [Abstract][Full Text] [Related]
13. Hemostatic effects of oral contraceptives in women who developed deep-vein thrombosis while using oral contraceptives.
Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Koster T; Bertina RM; Vandenbroucke JP
Thromb Haemost; 1998 Sep; 80(3):382-7. PubMed ID: 9759614
[TBL] [Abstract][Full Text] [Related]
14. Haemostatic changes and the oral contraceptive pill.
Norris LA; Bonnar J
Baillieres Clin Obstet Gynaecol; 1997 Sep; 11(3):545-64. PubMed ID: 9488791
[TBL] [Abstract][Full Text] [Related]
15. Thrombotic risk factors and oral contraception.
Bokarewa MI; Falk G; Sten-Linder M; Egberg N; Blombäck M; Bremme K
J Lab Clin Med; 1995 Sep; 126(3):294-8. PubMed ID: 7665978
[TBL] [Abstract][Full Text] [Related]
16. Oral contraceptives enhance the risk of clinical manifestation of venous thrombosis at a young age in females homozygous for factor V Leiden.
Rintelen C; Mannhalter C; Ireland H; Lane DA; Knöbl P; Lechner K; Pabinger I
Br J Haematol; 1996 May; 93(2):487-90. PubMed ID: 8639453
[TBL] [Abstract][Full Text] [Related]
17. First-time use of newer oral contraceptives and the risk of venous thromboembolism.
Suissa S; Blais L; Spitzer WO; Cusson J; Lewis M; Heinemann L
Contraception; 1997 Sep; 56(3):141-6. PubMed ID: 9347203
[TBL] [Abstract][Full Text] [Related]
18. End of the line for "third-generation-pill" controversy?
Vandenbroucke JP; Rosendaal FR
Lancet; 1997 Apr; 349(9059):1113-4. PubMed ID: 9113005
[TBL] [Abstract][Full Text] [Related]
19. Clinical aspects of the relationship between oral contraceptives and abnormalities of the hemostatic system: relation to the development of cardiovascular disease.
Kelleher CC
Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):392-5. PubMed ID: 2196811
[TBL] [Abstract][Full Text] [Related]
20. Resistance to activated protein C, associated with oral contraceptives use; effect of formulations, duration of assumption, and doses of oestro-progestins.
Olivieri O; Friso S; Manzato F; Grazioli S; Bernardi F; Lunghi B; Girelli D; Azzini M; Brocco G; Russo C; Corrocher R
Contraception; 1996 Sep; 54(3):149-52. PubMed ID: 8899255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
